miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors

Cancer Research

Volumn 74, Issue 16, 2014, Pages 4341-4352

  Gong, Chang ^a   Nie, Yan ^a   Qu, Shaohua ^a   Liao, Jian You ^a   Cui, Xiuying ^a   Yao, Herui ^a   Zeng, Yunjie ^a   Su, Fengxi ^a   Song, Erwei ^a   Liu, Qiang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL12 PROTEIN, HUMAN; MICRORNA; MIRN21 MICRORNA, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; SMAD7 PROTEIN; SMAD7 PROTEIN, HUMAN; STROMAL CELL DERIVED FACTOR 1;

ADULT; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CELL DIFFERENTIATION; CELL GROWTH; CYSTOSARCOMA PHYLLOIDES; DISEASE COURSE; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MYOFIBROBLAST; NUDE MOUSE; PATHOLOGY; PROGNOSIS; STROMA CELL; UPREGULATION; XENOGRAFT;

ADULT; ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CHEMOKINE CXCL12; DISEASE PROGRESSION; FEMALE; HETEROGRAFTS; HUMANS; MICE, NUDE; MICRORNAS; MYOFIBROBLASTS; PHYLLODES TUMOR; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SMAD7 PROTEIN; STROMAL CELLS; TRANSFECTION; UP-REGULATION;

EID: 84905993559     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0125     Document Type: Article

References (40)

1. Pimiento JM, Gadgil PV, Santillan AA, Lee MC, Esposito NN, Kiluk JV, et al. Phyllodes tumors: race-related differences. J Am Coll Surg 2011;213:537-42.
2. Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 2000;89:1502-11.
3. Barth RJ, Jr. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. Breast Cancer Res Treat 1999;57:291-5.
4. Shpitz B, Bomstein Y, Sternberg A, Klein E, Tiomkin V, Kaufman A, et al. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features. J Surg Oncol 2002;79:86 -92.
5. Jones AM, Mitter R, Springall R, Graham T, Winter E, Gillett C, et al. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. J Pathol 2008;214:533-44. (Pubitemid 351482269)
6. Azzopardi JG, Ahmed A, Millis RR. Problems in breast pathology. Major Probl Pathol 1979;11:i-xvi, 1-466.
7. Khan SA, Badve S. Phyllodes tumors of the breast. Curr Treat Options Oncol 2001;2:139-47.
8. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, et al. Diversity, topographic differentiation, and positionalmemory in human fibroblasts. Proc Natl Acad Sci U S A 2002;99:12877-82.
9. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
10. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissell MJ. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995;95:859-73.
11. Lieubeau B, Garrigue L, Barbieux I, Meflah K, Gregoire M. The role of transforming growth factor beta 1 in the fibroblastic reaction associated with rat colorectal tumor development. Cancer Res 1994;54:6526-32.
12. Tsukamoto H, Mishima Y, Hayashibe K, Sasase A. Alpha-smooth muscle actin expression in tumor and stromal cells of benign and malignant human pigment cell tumors. J Invest Dermatol 1992;98:116-20.
13. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-47. (Pubitemid 36818244)
14. Aranda FI, Laforga JB, Lopez JI. Phyllodes tumor of the breast. An immunohistochemical study of 28 cases with special attention to the role of myo fibroblasts. Pathol Res Pract 1994;190:474-81. (Pubitemid 24185160)
15. Wienholds E, Koudijs MJ, van Eeden FJ, Cuppen E, Plasterk RH. The microRNA-producing enzyme Dicer1 is essential for zebrafish development. Nat Genet 2003;35:217-8. (Pubitemid 37363173)
16. Yi R, O'Carroll D, Pasolli HA, Zhang Z, Dietrich FS, Tarakhovsky A, et al. Morphogenesis in skin is governed by discrete sets of differentially expressed microRNAs. Nat Genet 2006;38:356-62.
17. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-23. (Pubitemid 350235025)
18. Tang W, Yu F, Yao H, Cui X, Jiao Y, Lin L, et al. miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene 2014;33:2629-38.
19. Nie Y, Liu X, Qu S, Song E, Zou H, Gong C. Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival. Cancer Sci 2013;104:458-64.
20. Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med 2006;130:1516-21. (Pubitemid 44520719)
21. Noronha Y, Raza A, Hutchins B, Chase D, Garberoglio C, Chu P, et al. CD34, CD117, and Ki-67 expression in phyllodes tumor of the breast: an immunohistochemical study of 33 cases. Int J Surg Pathol 2010;19:152-8.
22. Kucuk U, Bayol U, Pala EE, Cumurcu S. Importance of P53, Ki-67 expression in the differential diagnosis of benign/malignant phyllodes tumors of the breast. Indian J Pathol Microbiol 2013;56:129-34.
23. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77. (Pubitemid 23118304)
24. Engel JM, Junger A, Hartmann B, Little S, Schnobel R, Mann V, et al. Performance and customization of 4 prognostic models for postoperative onset of nausea and vomiting in ear, nose, and throat surgery. J Clin Anesth 2006;18:256-63.
25. Wu Q, Yang Z, Wang F, Hu S, Yang L, Shi Y, et al. MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells. J Cell Sci 2013;126:4220-9.
26. Ohyagi-Hara C, Sawada K, Kamiura S, Tomita Y, Isobe A, Hashimoto K, et al. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin alpha5 expression. Am J Pathol 2013;182:1876-89.
27. Gong X, Zhang K, Wang Y, Wang J, Cui Y, Li S, et al. MicroRNA-130b targets Fmr1 and regulates embryonic neural progenitor cell proliferation and differentiation. Biochem Biophys Res Commun 2013;439:493-500.
28. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010;7:694-707.
29. Mishra S, Deng JJ, Gowda PS, Rao MK, Lin CL, Chen CL, et al. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene. 2013 Sep 16. [Epub ahead of print].
30. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fi brosis. J Exp Med 2010;207:1589-97.
31. Weinstein D, Strano S, Cohen P, Fields S, Gomori JM, Degani H. Breast fibroadenoma: mapping of pathophysiologic features with three-time-point, contrast-enhanced MR imaging - pilot study. Radiology 1999;210:233-40. (Pubitemid 29004310)
32. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 2013;105:849-59.
33. Hede K. MicroRNAs as onco-miRs, drivers of cancer. J Natl Cancer Inst 2010;102:1306-8.
34. Tahiri A, Leivonen SK, Luders T, Steinfeld I, Ragle Aure M, Geisler J, et al. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 2014;35:76-85.
35. Rask L, Balslev E, Jorgensen S, Eriksen J, Flyger H, Moller S, et al. High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. APMIS 2011;119:663-73.
36. Nouraee N, Van Roosbroeck K, Vasei M, Semnani S, Samaei NM, Naghshvar F, et al. Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma. PLoS ONE 2013;8: e73009.
37. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010;9:2423-33.
38. Hong L, Han Y, Zhang Y, Zhang H, Zhao Q, Wu K, et al. MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Targets 2013;17:1073-80.
39. 2/M checkpoint arrest in breast cancer cells. Radiat Oncol 2012;7:206.
40. Liu R, Li H, Liu L, Yu J, Ren X. Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biol Ther 2012;13:123-9.